NCT06020456View on ClinicalTrials.gov

Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A

CompletedOBSERVATIONAL
Enrollment

361

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2023

Study Completion Date

April 1, 2023

Conditions
Carrier of Hemophilia ADesmopressinFactor VIII Deficiency
Interventions
DRUG

Desmopressin

For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels

Trial Locations (12)

13385

Assistance publique hôpitaux de Marseille, Marseille

21079

University hospital of Dijon, Dijon

29609

University hospital of Brest, Brest

33604

University hospital of Bordeaux, Bordeaux

34295

University hospital of Montpellier, Montpellier

35033

University hospital of Rennes, Rennes

42055

University hospital of Saint Etienne, Saint-Etienne

44093

University hospital of Nantes, Nantes

54500

University hospital of Nancy, Nancy

59037

University hospital of Lille, Lille

69677

Hospices civils de Lyon, Bron

94270

University hospital of Bicêtre, Le Kremlin-Bicêtre

All Listed Sponsors
lead

Groupe Maladies hémorragiques de Bretagne

OTHER

NCT06020456 - Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A | Biotech Hunter | Biotech Hunter